Vascular Quality Initiative Surveillance of Femoropopliteal Artery Paclitaxel Devices

This study sought to determine the safety and efficacy of paclitaxel (PTX) devices in the treatment of peripheral artery disease involving the femoropopliteal artery. A meta-analysis of PTX devices for the treatment of femoropopliteal artery disease reported a mortality signal. This was a multicente...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular interventions 2021-12, Vol.14 (23), p.2598-2609
Main Authors: Bertges, Daniel J., Eldrup-Jorgensen, Jens, Robbins, Susan, Ssemaganda, Henry, Malone, Misti, Marinac-Dabic, Danica, Smale, Joshua, Lottes, Aaron E., Majithia, Arjun, Resnic, Frederic S.
Format: Article
Language:English
Subjects:
Angioplasty, Balloon
Cardiovascular Agents
Cohort Studies
drug-coated balloon
drug-eluting stent(s)
Drug-Eluting Stents
Femoral Artery - diagnostic imaging
Femoral Artery - surgery
Humans
mortality
Multicenter Studies as Topic
Paclitaxel
Peripheral Arterial Disease - drug therapy
Peripheral Arterial Disease - therapy
Popliteal Artery - diagnostic imaging
Popliteal Artery - surgery
Prospective Studies
registry
Treatment Outcome
Vascular Patency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study sought to determine the safety and efficacy of paclitaxel (PTX) devices in the treatment of peripheral artery disease involving the femoropopliteal artery. A meta-analysis of PTX devices for the treatment of femoropopliteal artery disease reported a mortality signal. This was a multicenter cohort study using an integrated clinical data surveillance system to conduct a prospective, propensity score–matched survival analysis of 2,456 patients in the Society for Vascular Surgery Vascular Quality Initiative from January 2017 to May 2020. The study compared PTX drug-coated balloon angioplasty versus percutaneous transluminal balloon angioplasty, PTX drug-eluting stents versus bare-metal stents, and any PTX device versus any non-PTX device. The primary outcome was 2-year survival. Secondary endpoints were successful ambulation and interventional success. Treatment with any PTX device versus any non-PTX device was associated with increased 2-year survival (89.5% vs 86.7%; HR: 0.79; 95% CI: 0.72-0.87; P = 0.004), improved interventional success (81.6% vs 77.6%; HR: 0.82; 95% CI: 0.74-0.91; P < 0.001), and higher rates of independent ambulation at 1 year (86.0% vs 83.4%; HR: 0.85; 95% CI: 0.79-0.91; P = 0.008). Treatment with PTX drug-coated balloon angioplasty was associated with improved survival at 2 years (88.9% vs 85.7%; HR: 0.77; 95% CI: 0.70-0.86; P = 0.005), while PTX drug-eluting stent therapy was associated with similar survival compared with bare-metal stent therapy (91.3% vs 89.6%; HR: 0.84; 95% CI: 0.70-1.01; P = 0.36). In this prospective, active surveillance of a national clinical registry, PTX-containing devices were associated with increased survival at 2 years and improved clinical outcomes at 1 year. (VQI DELTA Paclitaxel Device Safety Analysis [VQI-PTX]; NCT04110288) [Display omitted]
ISSN:1936-8798
1876-7605
DOI:10.1016/j.jcin.2021.08.058